Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Maruzzo

Showing results (111-120 of 150) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2023
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate CancerDavid Pook, Daniel M Geynisman, Joan Carles, et al.
Oncotarget|March 31, 2016
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinomaDaniele Santini, Matteo Santoni, Alessandro Conti, et al.
Clinical Genitourinary Cancer|April 14, 2024
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry StudyVeronica Mollica, Francesco Massari, Marco Maruzzo, et al.
The Oncologist|July 3, 2026
The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective StudyGiuseppe Neola, Fabiano Flauto, Carmine Caso, et al.
Cancers|May 16, 2023
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 StudySara Elena Rebuzzi, Matteo Brunelli, Francesca Galuppini, et al.
Tumori|April 15, 2025
From walls to wonder: Talking about spaces tailored for adolescents and young adults with cancerCarlo Alfredo Clerici, Francesca Scotti, Elena Pagani Bagliacca, et al.
Clinical & Experimental Metastasis|February 16, 2024
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinationsMichele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, et al.
Future Oncology (London, England)|June 11, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
Future Oncology (London, England)|April 29, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
Immunotherapy|January 20, 2025
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinationsMatilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, et al.
Pageof 15

Showing results (111-120 of 150) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2023
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate CancerDavid Pook, Daniel M Geynisman, Joan Carles, et al.
Oncotarget|March 31, 2016
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinomaDaniele Santini, Matteo Santoni, Alessandro Conti, et al.
Clinical Genitourinary Cancer|April 14, 2024
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry StudyVeronica Mollica, Francesco Massari, Marco Maruzzo, et al.
The Oncologist|July 3, 2026
The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective StudyGiuseppe Neola, Fabiano Flauto, Carmine Caso, et al.
Cancers|May 16, 2023
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 StudySara Elena Rebuzzi, Matteo Brunelli, Francesca Galuppini, et al.
Tumori|April 15, 2025
From walls to wonder: Talking about spaces tailored for adolescents and young adults with cancerCarlo Alfredo Clerici, Francesca Scotti, Elena Pagani Bagliacca, et al.
Clinical & Experimental Metastasis|February 16, 2024
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinationsMichele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, et al.
Future Oncology (London, England)|June 11, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
Future Oncology (London, England)|April 29, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
Immunotherapy|January 20, 2025
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinationsMatilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, et al.
Pageof 15